Jump to content

User:Jennifer Sereno/sandbox: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
removing non-free image in violation of WP:NFCC#9 -- it can be restored if/when the article goes live
Line 5: Line 5:
Established in 1998 to advance [[stem cell]] technology, '''WiCell Research Institute''' is a [[nonprofit organization]] that creates and distributes human pluripotent [[stem cell]] lines worldwide. WiCell also provides [[cytogenetics|cytogenetic]] and technical services, establishes scientific protocols and supports [[pure research|basic research]] on the [[University of Wisconsin–Madison]] campus.
Established in 1998 to advance [[stem cell]] technology, '''WiCell Research Institute''' is a [[nonprofit organization]] that creates and distributes human pluripotent [[stem cell]] lines worldwide. WiCell also provides [[cytogenetics|cytogenetic]] and technical services, establishes scientific protocols and supports [[pure research|basic research]] on the [[University of Wisconsin–Madison]] campus.


[[Image:WiCell_2013.jpg|thumb|right|250px|WiCell Research Institute]]
<!--[[Image:WiCell_2013.jpg|thumb|right|250px|WiCell Research Institute]]-->


Based in [[Madison, Wisconsin]], WiCell serves as home to the Wisconsin International Stem Cell Bank. This stem cell repository stores, characterizes and provides access to stem cell lines for use in research and clinical development. The cell bank originally stored the first five human [[Embryonic stem cell]] lines derived by Dr. [[James Thomson (cell biologist)|James Thomson]] of UW–Madison. It currently houses human embryonic stem cell lines, [[Induced pluripotent stem cell|induced pluripotent stem cell]] lines, clinical grade cell lines developed in accordance with [[Good manufacturing practice|Good Manufacturing Practices (GMP)]] and differentiated cell lines including neural [[Progenitor cell|progenitor cells]].
Based in [[Madison, Wisconsin]], WiCell serves as home to the Wisconsin International Stem Cell Bank. This stem cell repository stores, characterizes and provides access to stem cell lines for use in research and clinical development. The cell bank originally stored the first five human [[Embryonic stem cell]] lines derived by Dr. [[James Thomson (cell biologist)|James Thomson]] of UW–Madison. It currently houses human embryonic stem cell lines, [[Induced pluripotent stem cell|induced pluripotent stem cell]] lines, clinical grade cell lines developed in accordance with [[Good manufacturing practice|Good Manufacturing Practices (GMP)]] and differentiated cell lines including neural [[Progenitor cell|progenitor cells]].

Revision as of 21:16, 5 February 2013

History

Established in 1998 to advance stem cell technology, WiCell Research Institute is a nonprofit organization that creates and distributes human pluripotent stem cell lines worldwide. WiCell also provides cytogenetic and technical services, establishes scientific protocols and supports basic research on the University of Wisconsin–Madison campus.


Based in Madison, Wisconsin, WiCell serves as home to the Wisconsin International Stem Cell Bank. This stem cell repository stores, characterizes and provides access to stem cell lines for use in research and clinical development. The cell bank originally stored the first five human Embryonic stem cell lines derived by Dr. James Thomson of UW–Madison. It currently houses human embryonic stem cell lines, induced pluripotent stem cell lines, clinical grade cell lines developed in accordance with Good Manufacturing Practices (GMP) and differentiated cell lines including neural progenitor cells.

To support continued progress in the field and help unlock the therapeutic potential of stem cells, in 2005 WiCell began providing cytogenetic services and quality control testing services. These services allow scientists to identify genetic abnormalities in cells or changes in stem cell colonies that might affect research results.

Organization

WiCell operates as an affiliate of the Wisconsin Alumni Research Foundation. Chartered as an independent supporting organization of UW–Madison, WiCell collaborates with faculty members and provides support with stem cell research projects. The institute established its cytogenetic laboratory to meet the growing needs of academic and commercial researchers to monitor genetic stability in stem cell cultures.

Facilities

WiCell maintains its stem cell banking facilities, testing and quality assurance laboratories and scientific team in UW–Madison’s University Research Park.

UW–Madison faculty members use the institute’s laboratory space to conduct research, improve stem cell culture techniques and develop materials used in stem cell research.

To ensure the therapeutic relevance of its cell lines, WiCell banks clinical grade cells under GMP guidelines. The organization works cooperatively with Waisman Biomanufacturing, a provider of cGMP manufacturing services for materials and therapeutics qualified for human clinical trials.

Selected technologies

The following technologies employed by WiCell allow scientists to conduct stem cell research with greater assurance of reproducible results, an expectation for publication in peer-reviewed journals. Scientific tools and services include:

  • G-banded karyotyping, a baseline genomic screen that helps monitor genetic stability as cell colonies grow;
  • Spectral karyotyping, which may be used as an adjunct to g-banded karyotyping and helps define complex rearrangements as well as genetic marker chromosomes;
  • CGH, SNP, and CGH + SNP Microarrays, which detect genomic gains and losses as well as copy number changes;
  • Fluorescence in situ hybridization (FISH), a test used to confirm findings and screen for microdeletions or duplications of known targets;
  • fastFISH, a rapid screen for large numbers of clones and a cost-effective tool for monitoring aneuploidy; and
  • Short Tandem Repeat Analysis, which may be used to monitor the identity of a cell line and confirm the relationship of induced pluripotent stem cells to their parent.

Further Reading

Ludwig, TE; Levenstein, ME; Jones, JM; Berggren, WT; Mitchen, ER; Frane, JL; Crandall, LJ; Daigh, CA; Conard, KR; Piekarczyk, MS; Llanas, RA; Thomson, JA (2006). “Derivation of human embryonic stem cells in defined conditions.” Nature Biotechnology 24, 185-187. doi:10.1038/nbt1177. PMID 16388305

Ludwig, TE; Bergendahl, V; Levenstein, ME; Yu, J; Probasco, MD; Thomson JA (2006). “Feeder-independent culture of human embryonic stem cells.” Nature Methods 3, 637-646. doi:10.1038/nmeth902. PMID 16862139

Martins-Taylor, K; Nisler, BS; Taapken, SM; Compton, T; Crandall, L; Montgomery, KD; Lalande, M; Xu, RH (2011). “Recurrent copy number variations in human induced pluripotent stem cells.” Nature Biotechnology 29, 488-491. doi:10.1038/nbt.1890. PMID 21654665.

Taapken, SM; Nisler, BS; Newton, MA; Sampsell-Barron, TL; Leonhard, KA; McIntire, EM; Montgomery, KD (2011). “Karotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells.” Nature Biotechnology 29, 313-314. doi:10.1038/nbt.1835. PMID 21478842.

Howden, SE; Gore, A; Li, Z; Fung, HL; Nisler, BS; Nie, J; Chen, G; McIntosh, BE; Gulbranson, DR; Diol, NR; Taapken, SM; Vereide, DT; Montgomery, KD; Zhang, K; Gamm, DM; Thomson, JA. (2011) “Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy.” Proceedings of the National Academy of Sciences, vol. 108, no. 16, 6537–6542. doi: 10.1073/pnas.1103388108. PMID 21464322